Capricor Therapeutics, Inc.
CAPRHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeCapricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD). The company carries a $546.5M market cap, placing it firmly in the small-cap category. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD.
Market Cap
$546.5M
Beta
0.72
P/E (TTM)
—
P/E (Fwd)
-6.36
EPS (TTM)
$-2.45
EPS (Fwd)
$-1.48
ROE
-73.7%
ROA
-33.6%
Cash
$237.9M
Total Debt
$91.0M
Free CF
-$89.2M
52W Change
45.1%
Annual Financials
Cash vs Debt
Where CAPR stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, CAPR finished 58.79% below its 150-day moving average ($24.00) and 57.61% below its 200-day moving average ($23.33). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CAPR overbought or oversold?
At the September 3, 2026 close, CAPR's RSI(14) was 75.9, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Capricor Therapeutics, Inc. holds $237.9M in cash against $91.0M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$89.2M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -73.7% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $2.6M (2022) to $0 (2025), a 100% decline worth watching.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Capricor Therapeutics, Inc.'s trajectory.